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Histamine H3 receptor density is negatively
correlated with neural activity related to
working memory in humans
Takehito Ito1, Yasuyuki Kimura1, Chie Seki1, Masanori Ichise1, Keita Yokokawa1, Kazunori Kawamura2,
Hidehiko Takahashi3, Makoto Higuchi1, Ming-Rong Zhang2, Tetsuya Suhara1 and Makiko Yamada1*
Abstract
Background: The histamine H3 receptor is regarded as a drug target for cognitive impairments in psychiatric
disorders. H3 receptors are expressed in neocortical areas, including the prefrontal cortex, the key region of
cognitive functions such as working memory. However, the role of prefrontal H3 receptors in working memory has
not yet been clarified. Therefore, using functional magnetic resonance imaging (fMRI) and positron emission
tomography (PET) techniques, we aimed to investigate the association between the neural activity of working
memory and the density of H3 receptors in the prefrontal cortex.
Findings: Ten healthy volunteers underwent both fMRI and PET scans. The N-back task was used to assess the
neural activities related to working memory. H3 receptor density was measured with the selective PET radioligand
[11C] TASP457. The neural activity of the right dorsolateral prefrontal cortex during the performance of the N-back
task was negatively correlated with the density of H3 receptors in this region.
Conclusions: Higher neural activity of working memory was associated with lower H3 receptor density in the right
dorsolateral prefrontal cortex. This finding elucidates the role of H3 receptors in working memory and indicates the
potential of H3 receptors as a therapeutic target for the cognitive impairments associated with neuropsychiatric
disorders.
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Findings
Background
Working memory, the ability to retain information for a
short period of time [1], is regarded as a core cognitive
function that underpins a wide range of complex behav-
iours such as problem solving, decision-making and rea-
soning. A substantial number of neuroimaging studies
using fMRI have shown that the dorsolateral prefrontal
cortex (DLPFC) is the key cortical region involved in
working memory [2]. Moreover, several neurotransmit-
ters are known to be involved in this process.
Among the multiple neurotransmitter systems, compo-
nents of histaminergic neurotransmission, particularly H3
receptors, are known to modulate working memory in ani-
mals [3]. The H3 receptor is a presynaptic receptor that reg-
ulates the release of histamine (as an autoreceptor) as well
as other neurotransmitters such as dopamine, norepineph-
rine and acetylcholine (as a heteroreceptor), which are in-
volved in cognitive function [3]. More specifically,
increased release of histamine via H3 receptor antagonists
has been shown to improve working memory in rats under
various maze tasks and the delayed match-to-sample test
[3]. Thus, extensive preclinical studies have assessed the
role of H3 receptors in working memory. However, very
few such studies have been conducted in humans, and the
published clinical studies of H3 receptor antagonist/inverse
agonists have shown the mixed results of cognitive im-
provements in neuropsychiatric diseases ([4, 5] for review).
For example, some studies reported the positive effects of
H3 receptor drugs in episodic memory in Alzheimer’s
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disease, while others found no beneficial effects examined
by various drugs in different diseases [5]. These unclear
therapeutic effects may come from the complex biology
and pharmacology of H3 receptor, such as the heterogeneity
of isoforms and the different profile of drug activity (full ag-
onists, partial agonists, neutral antagonists, inverse agonists
and protean ligands) [5].
Nevertheless, H3 receptors are highly expressed in
the human cerebral cortex and basal ganglia, as re-
vealed by autoradiographic studies of post-mortem
brain tissue and by recent PET studies using radioligands
targeting H3 receptors [3, 6]. Furthermore, a post-mortem
brain sample study revealed that the prefrontal cortex of
schizophrenia patients with cognitive impairments showed
increased H3 receptor binding [7].
Thus, because the prefrontal cortex is the key region
for working memory and H3 receptors are highly
expressed in this region, the present study aimed to clar-
ify whether brain activity related to working memory
was associated with H3 receptor density in the prefrontal
cortex. To accomplish this, we used fMRI as well as PET
with the radioligand [11C] TASP457, which has high af-
finity and selectivity for H3 receptors [6, 8].
Methods
Participants
Ten right-handed (self-reported) healthy male volunteers
(mean age ± standard deviation, 25 ± 4 years) partici-
pated in the study. All participants had no history of
neurological and psychiatric disorders and were not tak-
ing any medications. The subjects underwent an fMRI
with N-back task followed by a PET scan at rest, with
the mean interval of 18.8 ± 20.6 days (mean ± standard
deviation).
Radioligand preparation
The [11C] TASP457 precursor and standard used in this
study were provided by Taisho Pharmaceutical Co., Ltd.
[11C] TASP457 was radiosynthesised by O-alkylation of the
2-pirydone-containing precursor (desmethyl TASP457) with
[11C] methyl triflate [4]. At a time of administration, the
radiochemical purity of [11C] TASP457 was > 95%, and its
specific activity was > 37 GBq/μmol.
PET procedures
After intravenous injection of [11C] TASP457 (390 ± 6 MBq
with molar activity of 92 ± 32 GBq/μmol), we acquired
three-dimensional dynamic images with a PET camera
(Eminence SET-3000GCT/X, Shimadzu, Kyoto, Japan)
for 120 min in 39 frames of increasing duration (from
10 s to 5 min). All PET images were reconstructed
using the filtered back-projection method (Gaussian
filter, kernel 5 mm; the reconstructed in-plane reso-
lution was 7.5 mm in full width at half maximum
(FWHM); voxel size 2 × 2 × 2.6 mm) corrected for
attenuation, randoms, scatter and head motion.
Plasma input functions were measured with arterial
blood sampling and metabolite analyses using a radio
high-performance liquid chromatography, as described
previously [6].
fMRI procedures
We designed a modified version of the N-back task used
in a previous study [2]. Participants responded to the
numeric characters of previously seen stimuli according
to three conditions, 0-, 1- and 2-backs.
A Siemens Verio 3 T MRI system (Siemens, Erlangen,
Germany) was used to obtain T2*-weighted echo-planar
imaging (repetition time [TR] = 2000 ms, echo time
[TE] = 25 ms, slice number = 33 (interleaved), slice thick-
ness = 3.8 mm, matrixes = 64 × 64, 345 volumes) with bold
oxygen level-dependent (BOLD) contrasts and structural
T1 image (TR = 2300 ms, TE = 1.95 ms, slice number =
176, slice thickness = 1 mm, matrixes = 256 × 256).
Preprocessing analysis with SPM8 software (Wellcome
Department of Cognitive Neurology, London, UK) in-
cluded slice time correction, realignment, DARTEL nor-
malisation and smoothing with a 6-mm FWHM
Gaussian kernel. First-level analysis modelled the task as
a block design, with working memory load as a linear re-
gressor (0-back = − 1, 1-back = 0, 2-back = 1). Six realign-
ment parameters and two derivatives were used as
covariates. Artefacts in fMRI time series data were de-
tected and corrected using robust weighted least squares
[9]. A mask image of the prefrontal cortex (including
Brodmann areas 8, 9, 10, 11, 12, 13, 14, 24, 25, 32, 44,
45, 46 and 47) was created using WFU PickAtlas 3.0.5
software (Wake Forest University, Winston-Salem, NC).
Group-level random effect analysis was performed to
identify the activity corresponding to increased working
memory load within the prefrontal cortex, using a
threshold of P < 0.001 (uncorrected) with a minimum
cluster size of 20 voxels [10]. Age was included as a
nuisance covariate.
PET and fMRI analyses
The contrast coefficients (ß value) were extracted from
the cluster images of increased working memory load.
Time–activity curves were generated using data ex-
tracted from the PET images by applying the spherical
(radius 4 mm) regions of interest images centred on the
peak coordinates of each cluster. Total distribution vol-
ume (VT), which reflects the H3 receptor density in the
brain, was calculated using Ichise’s multilinear analysis
(MA1) [11] with the time–activity curves for the initial
60 min and plasma input functions according to the pre-
vious quantitative analysis of [11C] TASP457–PET data
[6]. The correlation analyses between MRI (ß value) and
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PET (VT) data were conducted with IBM SPSS Statistics,
version 23 (IBM Corp., Armonk, NY). To compensate for
the small sample size, we used a resampling procedure
based on 5000 bootstrapped samples, using bias-correlated
and accelerated (BCa) 95% confidence intervals (CIs) to es-




There were no significant differences in accuracy across the
three N-back tasks (0-back, 98.0 ± 0.7%; 1-back, 98.1 ± 0.8;
2-back, 97.1 ± 1.1; Friedman test P = 0.66, χ2 = 0.84, df = 2).
The performances of 1- and 2-backs showed the ceiling ef-
fects as they were not significantly different from the max-
imum accuracy of 100% (Wilcoxon signed-rank tests both
Ps > 0.05, bothWs = − 15); thus, the behavioural data were
not used for further analyses to avoid spurious estimates.
Imaging data
Three clusters, in which neural activities assessed by fMRI
were associated with increased working memory load,
were detected in the bilateral DLPFC (the left middle
frontal gyrus, left superior frontal gyrus and right middle
frontal gyrus; Table 1). Their VT values (mL/cm
3),
estimated from PET data, were 7.4 ± 0.6 for the left
middle frontal gyrus, 7.2 ± 0.9 for the left superior
frontal gyrus and 7.0 ± 0.6 for the right middle frontal
gyrus. The ß value of the right middle frontal gyrus
(Fig. 1a) was negatively correlated with the VT value
of this region (Spearman r = − 0.65, P = 0.043, 95%
BCa CI = (− 0.91, − 0.05), bias = 0.063, standard error
= 0.21, Fig. 1b). No significant correlations were found
in the other two clusters.
Discussion
The present study revealed that higher activity in the
right DLPFC due to increased working memory load,
which was consistent with the findings of previous
studies [1, 2], was associated with lower density of H3
receptors. Preclinical studies demonstrated that H3 re-
ceptor blockade with H3 antagonists increased the re-
lease of neurotransmitters such as acetylcholine and
dopamine, resulting in enhanced cognition, whereas H3
agonists impaired cognition [3]. Enhanced cognition has
also been reported in H3 receptor knockout rodents [3].
Thus, the individual variability of H3 receptor density
may reflect the ability of neurotransmitter release. Taken
together with our findings, these results indicate that in-
hibition of H3 receptors, which increases the release of
histamine and other neurotransmitters, plays a role in
working memory activation in the right DLPFC.
Although very few studies have investigated the role
of H3 receptors in working memory in humans, one
fMRI study revealed that an increase in histamine
neurotransmission induced by betahistine (H3 antag-
onist/H1 agonist) moderately increased right DLPFC
activity during N-back task performance [12]. This
finding also supports the role of the H3 receptor
Table 1 Neural activity as a function of increased working
memory load
Region Side BA Cluster size Z value x y z
Middle frontal gyrus Left 9 83 3.91 − 28 32 34
Superior frontal gyrus Left 8 45 3.53 − 26 8 60
Middle frontal gyrus Right 8 21 3.33 28 10 60
(x, y, z) corresponds to Montreal Neurological Institute (MNI) coordinates
BA Brodmann area
Fig. 1 a Group map showing the activity in the right middle frontal gyrus (red, x, y, z = 28, 10, 60) in response to increased working memory load. b
The activity in the right middle frontal gyrus was negatively correlated with the H3 receptor radioligand retention (VT), which reflects the H3 receptor
density. The dashed lines indicate 95% confidence intervals. The PET image on the graph indicates the distribution of the H3 receptors in the brain.
The sagittal image was obtained by averaging parametric images of the 10 subjects. The parametric images were calculated using Ichise’s multilinear
analysis to estimate total distribution volume for each voxel and spatially normalised thereafter. The circle indicates the location of the activated region
detected in fMRI during performing working memory task in the right middle frontal gyrus shown in a
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inhibition in DLPFC activation, consistent with our
study results.
One of the key limitations of this study is its small
sample size, which decreased its statistical power. More-
over, we were unable to establish a causal relationship
between H3 receptor density and working memory activ-
ity in the DLPFC or to examine the association between
H3 receptors and working memory performance. Further
studies with a larger sample size and the use of H3 ago-
nists/antagonists are required to establish the causal re-
lationship between H3 receptors and working memory
activity and its performance.
Conclusion
In conclusion, the present study showed for the first time
that H3 receptor density was associated with working
memory activity in the right DLPFC in humans, revealing
a histaminergic mechanism underlying working memory.
This finding supports the potential of histaminergic mod-
ulators, especially those that affect H3 receptors, for treat-
ing cognitive impairments in neuropsychiatric disorders.
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